Code Pharma reported encouraging eight-week results for its HIV drug, Gammora, highlighting its potential to target HIV at the cellular level. The findings were shared at the 2024 HIV Drug Therapy Conference in Glasgow, Scotland.
“These incredibly positive outcomes offer new hope at a time when 40 million individuals worldwide are impacted by HIV and the current standard of care with ART drugs does not offer a cure at the cellular level,” said Eynat Finkelshtein, PhD., Chief Scientific Officer of Code Pharma.